Celldex Therapeutics (CLDX) Stock: Buy, Sell, or Hold?
CLDX - Celldex Therapeutics, Inc
$32.18
-0.23 (-0.71%)
▼
5d:
+2.22%
30d:
-17.99%
90d:
-16.13%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 23, 2026 at $30.69 · last confirmed Oct 1, 2026
Strength: 6.6/10
Get Alerted When CLDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CLDX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CLDX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CLDX is currently trading at $32.18, which is considered oversold relative to its 30-day fair value range of $33.91 to $40.64.
Technical Outlook: Technically, CLDX is in a uptrend. Immediate support is located at $30.38, while resistance sits at $41.62.
Market Sentiment: CLDX scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $63.07 (+94.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CLDX is in a uptrend. Immediate support is located at $30.38, while resistance sits at $41.62.
Market Sentiment: CLDX scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $63.07 (+94.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$33.91 -
$40.64
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 94.6% below Wall St target ($63.07)
- CAUTION: Bottoming setup, but lagging the sector by 31% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$33.91 -
$40.64
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$30.38
Resistance Level
$41.62
Current Trend
Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.65
Wall Street Target
$63.07
(+94.6%)
Revenue Growth (YoY)
-97.0%
Share & Embed Analysis
Last updated: October 01, 2026 4:07 PM ET
Data refreshes hourly during market hours. Next update: 5:07 PM
Data refreshes hourly during market hours. Next update: 5:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLDX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 51 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 53 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 47 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$141 | 67 BUY |
